FDA QSR 820 vs QMSR (Quality System Regulation) Transition Guide
Introducing U.S. FDA’s transition timeline from 21 CFR Part 820 (QSR) to the new QMSR, detailing core changes and how to align QMS using ISO 13485:2016.
The U.S. FDA has finalized its Quality System Regulation (QMSR), replacing the decades-old 21 CFR Part 820 (QSR). The QMSR incorporates ISO 13485:2016 requirements by reference, supplemented by specific FDA regulatory definitions (record retention, labeling/packaging, medical device reporting MDR). The transition deadline is February 2, 2026.
Three Critical Changes Under QMSR
While aligning QMS to ISO 13485 reduces audit redundancy for global manufacturers, FDA inspections will remain rigorous. Pay special attention to the following aspects.
- Electronic signatures (21 CFR Part 11): electronic logs must remain compliant, which is not detailed in ISO 13485
- Labeling & packaging: FDA preserves specific rules for label copy and listing reviews beyond ISO 13485
- FDA readiness: inspection models (QSIT) will transition to audit protocols matching ISO 13485 terms
FAQ
Can an ISO 13485 certificate replace an FDA inspection after QMSR implementation?+
No. The FDA clarified it will continue to perform routine and foreign facility inspections. An ISO 13485 certificate does not exempt a manufacturer, but the inspectors will evaluate compliance against the QMSR framework.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
